🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎙️NEW #AHA24 Interview 💫Dr Marc Bonaca MD MPH discusses new insights from the CLEAR OUTCOMES trial on #bempedoic acid in statin-intolerant patients with #PAD. 📽️Watch here👉 ow.ly/mFRo50UigSK #AHA2024 #CardioTwitter

Grateful to be part of #SIC2024 Italian Cardiologists Of Tomorrow SIC Società Italiana di Cardiologia

Introducing the #VMJ NextGen Editorial Board Cohort #3: Drs Nichole Brunton, Mario Enrico Canonico, Harish Eswaran, Amanda Morrison, Sonal Pruthi, Sneha Thomas, Francisco Ujueta Nichole Brunton, DO Mario Enrico Canonico Sonal Pruthi Sneha Thomas @ujuetafrancisco

PRO-HF trial tested if routine use of KCCQ in HF clinics improves QoL. No significant difference in QoL or clinical outcomes at 1 year. Future work needed to optimize PRO integration. Summary in #HREV (link.springer.com/article/10.100…). Mario Enrico Canonico Marc Samsky Alex Sandhu Jimmy Zheng

📰A professional update 🔥 My recent boss, mentor, and friend Mikhail Kosiborod recently left Saint Luke's Mid America Heart Institute and Saint Luke's to lead late-stage CVRM development for AstraZeneca. As a result, I am assuming a number of vacated leadership roles, including: Executive Director,

The definition & management of fragility remain a challenge in PAD. Marc Bonaca MD MPH CPC Clinical Research CU Department of Medicine Attached is a recent thread of papers in JACC Journals American College of Cardiology jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.… jacc.org/doi/10.1016/j.… jacc.org/doi/epdf/10.10…

Sex Differences in Peripheral Vascular Disease #AHAJournals ahajournals.org/doi/10.1161/CI…

Acute Heart Failure is an umbrella definition including multiple causes, different clinical presentations and variable prognosis. What are the data about Non-Ischemic Cardiomyopathies? Look at our comprehensive and critical review mdpi.com/2075-4418/15/5…

Here’s my guide to navigate the #ACC25 trials, coming this weekend and featured in many journals with a (very) high impact factor. 1. WARRIOR = Intensive medical therapy in women with ANOCA/INOCA 2. STRIDE = Semaglutide in type 2 diabetes and peripheral artery disease 3. API-CAT

Exciting #STRIDE trial results on #semaglutide in #PAD & type 2 #DM, presented by Marc Bonaca MD MPH at #ACC25! CPC Clinical Research CU Cardiology The Lancet American College of Cardiology

Do our hypertension treatments have the same effectiveness onset in HFpEF? We tried to answer this question with a reconstructed time-to-event meta-analysis of randomized controlled trials. Now on EJPC! Alessandro Villaschi Mario Enrico Canonico Daniele Rodolico academic.oup.com/eurjpc/article…

Some of the many faces of #VMJ Editorial Board - always a pleasure to meet with this group! #VascularMedicine Heather L Gornik Valerie K Clark @SVM_Tweets

Thrilled to join #EASCongress2025 to present data on bempedoic acid in patients with PAD! CPC Clinical Research CU Department of Medicine Marc Bonaca MD MPH EAS Congress European Atherosclerosis Society

Exciting day with more obicetrapib data for at ⁦⁦European Atherosclerosis Society⁩ with publications in ⁦NEJM⁩ and ⁦The Lancet⁩ ⁦John Kastelein⁩ ⁦Prof Kausik Ray FMedSci⁩ ⁦Michael Davidson MD⁩ ⁦Adam Nelson⁩ ⁦Julie Butters⁩ ⁦Monash Victorian Heart Institute⁩ ⁦NewAmsterdam Pharma Corporation⁩

Endpoint specificity and cause of death in CV trials: our experience from the MARINER trial CPC Clinical Research Marc Bonaca MD MPH JACC Journals #JACCAdvances sciencedirect.com/science/articl…

Loop diuretics are vital in HF, but gut edema may limit oral absorption. Bumetanide Nasal Spray (BNS) bypasses the gut, offering rapid, high-bioavailability delivery. A new study shows BNS is bioequivalent to oral forms (link.springer.com/article/10.100…). HREV AEs Jan Biegus Mario Enrico Canonico

Great work led by Giuseppe Gargiulo

HFpEF affects ~4M in the U.S. Once lacking therapies, HFpEF is now seeing rapid progress—with SGLT2i, Ns-MRAs, and GLP-1 RAs offering hope, especially for the obesity phenotype. (link.springer.com/article/10.100…). #HREV Josephine Harrington, MD Marc Bonaca MD MPH Andrew J Sauer MD orlyvardeny Mario Enrico Canonico

Current evidence and future perspectives in HFpEF therapy. #HREV Josephine Harrington, MD Caio de Assis Moura Tavares Andrew P. Ambrosy, MD, MPH orlyvardeny Andrew J Sauer MD Marc Bonaca MD MPH CPC Clinical Research link.springer.com/article/10.100…

Congratulations to #Napoli. A sober city 😎☀️Felice Gragnano Mario Enrico Canonico